Amoeba SAS, a prominent player in the materials sector, specifically within the chemicals industry, has been making significant strides in the development of biological products and services aimed at mitigating microbiological risks across various sectors. Headquartered in Chassieu, France, the company has carved a niche for itself by leveraging the natural biocidal properties of the living amoeba Willaertia magna C2c Maky. This innovative approach has positioned Amoeba SAS as a leader in the treatment of water, surfaces, and chronic wounds, as well as in agricultural biocontrol technologies.
Incorporated in 2010, Amoeba SAS has consistently focused on addressing critical microbiological challenges. The company’s flagship technology harnesses the amoeba’s natural ability to combat harmful microorganisms, offering a sustainable and effective solution for water treatment and surface sanitation. This technology is particularly relevant in the health sector, where maintaining sterile environments is paramount. Additionally, Amoeba SAS’s agricultural biocontrol solutions target phytopathogenic microorganisms, providing farmers with a natural alternative to chemical pesticides.
Despite its innovative contributions, Amoeba SAS has faced financial challenges, as reflected in its recent financial metrics. As of May 4, 2026, the company’s close price stood at 0.87 EUR, a significant decline from its 52-week high of 1.398 EUR on May 7, 2025. The 52-week low was recorded at 0.78 EUR on March 26, 2026. The company’s market capitalization is currently valued at 67,671,952 EUR, with a price-to-earnings ratio of -6.04, indicating ongoing financial pressures.
Amoeba SAS is listed on the NYSE Euronext Paris, which provides it with a platform to engage with a broad investor base. The company’s strategic focus on sustainable and environmentally friendly solutions aligns with global trends towards green technologies and reduced reliance on chemical treatments. This alignment not only enhances its market appeal but also positions it favorably for potential partnerships and collaborations within the industry.
Looking ahead, Amoeba SAS is poised to capitalize on the growing demand for eco-friendly and biologically-based solutions. The company’s commitment to innovation and sustainability is likely to drive its future growth, despite current financial headwinds. As the global emphasis on environmental responsibility continues to intensify, Amoeba SAS’s unique offerings in water treatment, surface sanitation, and agricultural biocontrol are expected to gain further traction, potentially leading to a recovery in its financial performance and market valuation.
